サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1542855

血管免疫芽球性T細胞リンパ腫の世界市場：2024年～2031年

Global Angioimmunoblastic T-Cell Lymphoma Market - 2024-2031

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
血管免疫芽球性T細胞リンパ腫の世界市場：2024年～2031年
出版日: 2024年08月26日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界の血管免疫芽球性T細胞リンパ腫市場は、2023年に4億7,850万米ドルに達し、2031年には6億8,700万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは4.7%で成長する見込みです。

血管免疫芽球性T細胞リンパ腫（AITL）は非ホジキンリンパ腫（NHL）のまれなタイプで、リンパ球が制御不能に増殖することで発症します。これらのリンパ球は、免疫系の重要な部分である血液とリンパ系で体内を移動します。リンパ系は、リンパと呼ばれる液体を運ぶリンパ管で構成されており、リンパは体組織を循環し、多数の白血球を含んでいます。

市場力学：

促進要因と抑制要因

非ホジキンリンパ腫の有病率の上昇

非ホジキンリンパ腫患者数の増加により、AITLを含む様々な非ホジキンリンパ腫サブタイプに対する標的治療薬や個別化治療法の開発に注目が集まっています。製薬会社や研究機関は、このような患者集団のニーズに対応するための研究開発に投資する意欲を高めており、その結果、新薬や治療法が導入されています。例えば、米国国立衛生研究所によると、非ホジキンリンパ腫の新規発症率は、男女10万人当たり年間18.6人でした。死亡率は男女10万人当たり年間5.0人でした。

専門的治療法の限られた利用可能性

世界のAITL市場における重大な抑制要因の1つは、治療費が高く、専門的な治療法が限られていることです。標的療法やCAR-T細胞療法を含む先進的治療の多くには多額の経済的負担が伴うため、特に中低所得国では患者のアクセスが制限される可能性があります。

これらの治療法の製造は複雑で高コストであることに加え、AITL治療薬として承認されている薬剤の数が限られているため、これらの治療法を広く利用できるようにすることが課題となり、市場の成長を阻害しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 非ホジキンリンパ腫の有病率の上昇
      • 治療選択肢の進歩
    • 抑制要因
      • 専門的な治療法が限られていること
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 特許分析
  • PESTLE分析
  • SWOT分析
  • DMIオピニオン

第6章 薬剤タイプ別

  • アザシチジン
  • ブレンツキシマブ・ベドチン
  • ティピファルニブ
  • AUT04
  • MLN8237
  • CD7-CART
  • その他

第7章 投与経路別

  • 経口
  • 静脈内
  • その他

第8章 エンドユーザー別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第11章 企業プロファイル

  • Roche（Genentech）
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Bristol-Myers Squibb
  • Merck & Co
  • Pfizer Inc
  • Novartis
  • Celgene Corporation（Bristol-Myers Squibb company）
  • Gilead Sciences
  • AbbVie
  • Incyte Corporation
  • Janssen Pharmaceuticals（Johnson & Johnson）

第12章 付録

目次
Product Code: PH8580

Overview

Global angioimmunoblastic T-cell lymphoma Market reached US$ 478.5 million in 2023 and is expected to reach US$ 687 million by 2031, growing at a CAGR of 4.7% during the forecast period 2024-2031.

Angioimmunoblastic T-cell lymphoma (AITL) is a rare type of non-Hodgkin lymphoma (NHL) that develops when lymphocytes grow out of control. These lymphocytes move around the body in the blood and lymphatic system, which is an essential part of the immune system. The lymphatic system consists of lymph vessels that carry a liquid called lymph, which circulates around body tissues and contains a high number of white blood cells.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of non-Hodgkin lymphoma

The increasing number of NHL cases leads to a greater focus on developing targeted therapies and personalized treatment options for various NHL subtypes, including AITL. Pharmaceutical companies and research institutions are motivated to invest in research and development to address the needs of this patient population, resulting in the introduction of new drugs and therapies. For instance, according to the National Institutes of Health, the rate of new cases of non-Hodgkin lymphoma was 18.6 per 100,000 men and women per year. The death rate was 5.0 per 100,000 men and women per year.

Limited availability of specialized therapies

One significant restraint in the global AITL market is the high cost of treatment and limited availability of specialized therapies. Many of the advanced treatments, including targeted therapies and CAR-T cell therapies, come with substantial financial burdens that can restrict access for patients, especially in low- and middle-income countries.

The complexity and high cost of manufacturing these therapies, coupled with the limited number of approved drugs for AITL, pose challenges in making these treatments widely accessible, thereby inhibiting market growth.

Segment Analysis

The global angioimmunoblastic T-cell lymphoma market is segmented based on drug type, route of administration, distribution channel, and region.

The azacitidine from the drug type segment accounted for approximately 41.7% of the angioimmunoblastic t-cell lymphoma market share

The azacitidine from the drug type segment accounted for approximately 41.7%. Azacitidine is a crucial treatment for angioimmunoblastic T-cell lymphoma (AITL) due to its role in epigenetic regulation. It inhibits DNA methylation, reactivating tumor suppressor genes and enhancing the effectiveness of other therapies. It is often used in combination treatment, especially in cases where traditional chemotherapy is insufficient or patients experience relapse or refractory disease. Azacitidine targets underlying epigenetic abnormalities associated with AITL, improving clinical outcomes. However, its effectiveness varies among patients and may cause side effects like bone marrow suppression, anemia, and gastrointestinal disturbances. Therefore, its use is tailored to individual patient needs.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, FDA approvals, ongoing clinical trials and research studies, expansions, increased healthcare infrastructure, and others that help the region to grow during the forecast period.

For instance, in March 2023, Duvelisib treatment significantly improved response rates in patients with peripheral T-cell lymphoma (PTCL), with activity favoring those with PTCL not otherwise specified (NOS) and angioimmunoblastic T-cell lymphoma (AITL), according to histology-specific outcomes from the phase 2 PRIMO trial.

Market Segmentation

By Drug Type

  • Azacitidine
  • Brentuximab Vedotin
  • Tipifarnib
  • AUT04
  • MLN8237
  • CD7-CART
  • Others

By Route of Administration

  • Oral
  • Intravenous
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the market include Roche (Genentech), Bristol-Myers Squibb, Merck & Co, Pfizer Inc, Novartis, Celgene Corporation (Bristol-Myers Squibb Company), Gilead Sciences, AbbVie, Incyte Corporation, Janssen Pharmaceuticals (Johnson & Johnson) among others.

Key Developments

  • In May 2023, A phase 2 clinical trial by the University School of Medicine found that 90% of patients with an aggressive subtype of non-Hodgkin lymphoma have gone into remission. The trial, which included 17 patients with peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH), found that 80.2 percent of them had complete responses after a treatment course that combined a standard four-drug chemotherapy regimen with another drug called azaciditine.

Why Purchase the Report?

  • To visualize the global angioimmunoblastic T-cell lymphoma market segmentation based on drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of the angioimmunoblastic T-cell lymphoma market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global angioimmunoblastic T-cell lymphoma market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the prevalence of non-Hodgkin lymphoma
      • 4.1.1.2. Advancements in treatment options
    • 4.1.2. Restraints
      • 4.1.2.1. Limited availability of specialized therapies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. PESTLE Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Drug Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 6.1.2. Market Attractiveness Index, By Drug Type
  • 6.2. Azacitidine*
    • 6.2.1. Introduction
  • 6.3. Brentuximab Vedotin
  • 6.4. Tipifarnib
  • 6.5. AUT04
  • 6.6. MLN8237
  • 6.7. CD7-CART
  • 6.8. Others

7. By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.2. Market Attractiveness Index, By Route of Administration
  • 7.3. Oral*
    • 7.3.1. Introduction
    • 7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.4. Intravenous
  • 7.5. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospital Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. UK
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Roche (Genentech)*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Bristol-Myers Squibb
  • 11.3. Merck & Co
  • 11.4. Pfizer Inc
  • 11.5. Novartis
  • 11.6. Celgene Corporation (Bristol-Myers Squibb company)
  • 11.7. Gilead Sciences
  • 11.8. AbbVie
  • 11.9. Incyte Corporation
  • 11.10. Janssen Pharmaceuticals (Johnson & Johnson)

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us